Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOAC interruption versus continuation during elective coronary angiography or PCI
NL-OMON51007Recruiting
- Sponsor
- Zuyderland
- Start
- Sep 2022
- Countries
- 1
01
Overview
Open-label trial in Atrial fibrillation (AFib), coronary arteriosclerosis and Chronic Coronary Syndrome (CCS) (2 arms), sponsored by Zuyderland. Primary endpoint: In-hospital major bleeding. Started Sep 2022; status: recruiting.
02
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosisChronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on NL-OMON51007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51007.